Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest

Bone Marrow Transplantation volume 46, pages 314–316 (2011)Cite this article

Subjects

Plerixafor (Mozobil, AMD3100) is a bicyclam compound that reduces CD34+ hematopoietic stem cells (HSCs) anchoring to the BM microenvironment through reversible inhibition of the SDF-1α/CXCR4 axis.1, 2 It is synergistic with G-CSF, and when used together, this combination is useful in ‘poor mobilizer’ patients3 or whenever a high overall volume of CD34+ cells is needed, as with repetitive autotransplantation procedures.4 Apart from gastrointestinal discomfort, the drug is deemed to be sufficiently safe for use, in pilot studies, as a single agent for PBSC mobilization in normal donors before allogeneic hematopoietic transplantation.5, 6

The relatively short time required for the onset of measurable HSC mobilization to peripheral blood is also a distinct advantage with plerixafor.6 Typically, an upsurge in peripheral blood CD34+ cells is evident within 4–9 h after s.c. injection. This rapid effect is due to a nonreliance on modulation of cellular receptor or cytokine cascade, processes that are inherently slow. Based on its fast action, we have successfully used plerixafor for ‘emergency’ PBSC mobilization in a normal donor, for whom a routine BM harvest suddenly assumed disproportionate risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167: 4686–4692.

    Article  CAS  Google Scholar 

  2. Martin C, Bridger GJ, Rankin SM . Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol 2006; 134: 326–329.

    Article  CAS  Google Scholar 

  3. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  Google Scholar 

  4. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904–1912.

    Article  CAS  Google Scholar 

  5. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.

    Article  CAS  Google Scholar 

  6. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998.

    Article  CAS  Google Scholar 

  7. Xu H, Exner BG, Chilton PM, Tanner MK, Mueller YM, Rezzoug F et al. A delay in bone marrow transplantation after partial conditioning improves engraftment. Transplantation 2004; 77: 819–826.

    Article  Google Scholar 

  8. Xun C, Tsuchida M, Thompson J . Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997; 64: 297–302.

    Article  CAS  Google Scholar 

  9. Yunchuan D, Rotta M, Graves S, Storer B, Peterson LJ, Sale G et al. Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2009; 15: 1244–1250.

    Article  Google Scholar 

  10. Guidance to Accompany the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration, 4th edn. FACT Accreditation Office: Omaha, NE, USA; JACIE Accreditation Office: Barcelona, Spain, 2010 p. 89.

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Unit, Ospedale Ferrarotto, Azienda Ospedaliera Policlinico-Vittorio Emanuele, Catania, Italy

    S Leotta, M Poidomani, E Mauro, A Spadaro, E Marturano & G Milone

Authors
  1. S Leotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Poidomani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Mauro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Spadaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Marturano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Milone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Milone.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leotta, S., Poidomani, M., Mauro, E. et al. AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant 46, 314–316 (2011). https://doi.org/10.1038/bmt.2010.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.98

This article is cited by

Search

Advanced search

Quick links